



# Allergologia et immunopathologia

www.elsevier.es/ai



## ORIGINAL ARTICLE

# Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma

C. Lee\*, W.B. Klaustermeyer

Department of Medicine, Division of Allergy and Immunology, VA Greater Los Angeles Healthcare System/University of California Los Angeles, Los Angeles, CA, United States

Received 12 August 2011; accepted 7 November 2011

Available online 10 January 2012

### KEYWORDS

Asthma;  
Cell mediated  
immunity;  
Delayed type  
hypersensitivity skin  
test;  
Infection;  
Inhaled  
corticosteroids

### Abstract

**Background:** Cell mediated immunity is suppressed by systemic corticosteroids. Inhaled corticosteroids have been shown to affect parameters including bone metabolism, hypothalamus–pituitary adrenal axis, linear growth, and lead to the development of cataracts. However, it is unclear if high dose inhaled corticosteroid therapy affects cell mediated immunity. **Study objectives:** To evaluate if asthma patients taking high dose inhaled corticosteroids chronically have reduced cell mediated immunity compared to asthma patients not taking inhaled corticosteroids.

**Methods:** Eighteen asthmatic subjects participated in this cross-sectional study. Cell mediated immunity was evaluated in nine patients who had been taking high dose inhaled corticosteroids for >6 months and nine patients not taking inhaled corticosteroids. Cell mediated immunity was evaluated by delayed type hypersensitivity (DTH) skin testing with intradermal placement of candida and tetanus antigens.

**Results:** There was no significant difference in DTH skin test results between the high dose inhaled corticosteroid and no corticosteroid treated asthma group.

**Conclusion:** Patients with asthma taking high dose inhaled corticosteroids chronically (>6 months) did not have significantly greater impaired cell mediated immunity than patients not taking inhaled corticosteroids in this study.

© 2011 SEICAP. Published by Elsevier España, S.L. All rights reserved.

## Introduction

Asthma is a variable and chronic inflammatory disease of the airways. The inflammatory disorder underlying asthma arises from the interaction of various cells including eosinophils,

mast cells and T lymphocytes.<sup>1</sup> Thus, anti-inflammatory therapy, in the form of inhaled corticosteroids, is key in the management of persistent asthma.<sup>2</sup> As the prevalence of asthma has been increasing, so has the use of inhaled corticosteroids, and at higher doses than previously prescribed early in its introduction.

Recent studies have shown that inhaled corticosteroids have systemic effects on bone metabolism,<sup>3–8</sup> hypothalamus–pituitary adrenal axis,<sup>9–15</sup> on linear

\* Corresponding author.

E-mail address: [christina.h.lee@hotmail.com](mailto:christina.h.lee@hotmail.com) (C. Lee).

growth,<sup>16–18</sup> and cataracts.<sup>19–21</sup> Oral corticosteroids have an even more potent effect on these parameters, and additionally have been shown to suppress cell mediated immunity, increasing an individual's susceptibility of acquiring an opportunistic infection.<sup>22–31</sup>

It is unclear at this time whether high dose inhaled corticosteroids also suppress cell mediated immunity. Studies addressing this issue have been conflicting thus far.<sup>32–34</sup> Currently there are no data to suggest increased incidence or course of fungal, viral or bacterial infections with the use of inhaled corticosteroids. However, there are rare cases that have been reported of reactivation of tuberculosis or viral infections associated with the use of inhaled corticosteroids.<sup>35–37</sup> The US Food and Drug Administration has instructed the manufacturers of oral, injectable and inhaled corticosteroids to include the warning about the possible risk of tuberculosis and viral infections with the use of these agents.<sup>38</sup> However, the American Academy of Allergy and Immunology issued a position statement, stating that this warning is unwarranted.<sup>39</sup>

The objective of our current study was to evaluate if there is a correlation between high dose inhaled corticosteroids and suppression of cell mediated immunity in asthmatics. This was accomplished by determining if there was a statistically significant higher incidence of impaired cellular immunity (as reflected in anergy or lower cumulative skin test scores to DTH testing) in patients with asthma who have already been receiving high dose inhaled fluticasone for >6 months compared to an age-matched control asthma population not on high dose inhaled corticosteroids.

## Materials and methods

### Study design

Eighteen volunteers with asthma between the ages of 42 and 67 were recruited for this cross-sectional study. Informed consent was obtained from each subject prior to entry into the study and the protocol was approved by the local Institutional Review Board (IRB B, VA Promise No. 0035). Exclusion criteria included subjects who have received systemic corticosteroids or immunosuppressants in the past 6 months, patients with chronic diseases that may influence cell mediated immunity (autoimmune disease, malignancy or immunodeficiency), or patients with a significant infection in the past 6 months.

Group A consisted of nine asthma patients who had been compliant with taking high dose inhaled corticosteroids (defined as fluticasone/salmeterol 500/50 µg twice daily or fluticasone propionate 220 µg two puffs twice daily) for at least 6 months duration.

Group B consisted of nine volunteers with mild intermittent asthma who had been treated with albuterol as needed only, without exposure to inhaled corticosteroids.

Cell mediated immunity was compared between volunteers of group A and group B by DTH skin testing. To account for differences that may be related to age, each volunteer in group A was age matched within 3 years to a volunteer in group B, resulting in a comparable spread of age between the two groups.

**Table 1** DTH skin test results (millimetres of induration) evaluating cell mediated immunity in the inhaled corticosteroid group.

Subject	Candida (mm)	Tetanus (mm)	Candida + tetanus (mm)
1	0	10	10
2	0	7	7
3	0	0	0
4	6	7	13
5	0	5	5
6	0	3	3
7	6	7	13
8	0	5	5
9	18	0	18
Mean	3.33	4.89	8.22
SD	6.08	3.37	5.72
SEM	2.03	1.12	1.91

### DTH skin testing and interpretation

DTH skin testing was performed in our study using the standard Mantoux technique. Intradermal injections of 0.1 mL of candida (Candin; Allermid Laboratories; San Diego, CA, USA) and tetanus (Tetanus Toxoid USP; Aventis Pasteur) were placed on the volar aspect of the forearm. Results were read by a single blinded individual for all subjects 48 h after placement using the ballpoint pen technique to measure the induration at each site. Orthogonal diameters were measured, and the average of these diameters was recorded. A mean induration of  $\geq 2$  mm was considered positive. A cumulative skin test score was calculated by adding the mean diameters of positive reactions.

### Statistical analysis

The non-parametric Wilcoxon rank sum test and the parametric *t* test were both used to compute *p* values for comparing means between the inhaled corticosteroid group (group A) and the albuterol only (group B) in total skin test score for candida and tetanus individually, total skin test score for candida plus tetanus, as well as difference in incidence of anergy. A statistically significant result was defined as *p* < 0.05. Means  $\pm$  SEM are reported.

### Results

Eighteen volunteer subjects completed this study. Subjects ranged in age from 42 to 67 years (mean,  $57.11 \pm 6.6$ ). One subject in the study was lost to follow up. There were no significant adverse events experienced in the 18 subjects who completed the study. The most common complaint was mild pruritis at the site of skin testing.

Tables 1 and 2 depict the sum of mean orthogonal diameters for candida and tetanus skin test score individually as well as for the candida plus tetanus total skin test score for the high dose inhaled corticosteroid group (group A) and no inhaled corticosteroid group (group B), respectively. The mean candida skin test score of  $3.33 \pm 2.03$  mm and  $4.33 \pm 1.76$  in the inhaled corticosteroid group and

Download English Version:

<https://daneshyari.com/en/article/3339945>

Download Persian Version:

<https://daneshyari.com/article/3339945>

[Daneshyari.com](https://daneshyari.com)